logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies shares up as it launches new antibody discovery platform with US pharma group

The technology allows the selection of rare, fully human antibodies using what's called the DeepDisplay platform

Pictured are antibodies
Immunoprecise is a full-service, therapeutic antibody discovery company

Shares in ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) were higher on Tuesday as the group said it had launched a "powerful and unique" platform for therapeutic antibody discovery with a US pharma firm.

It expands the group's offerings and the technology allows the selection of rare, fully human antibodies using what's called DeepDisplay, which is a combination of transgenic animal immunization and custom antibody selections, the company said.

READ: ImmunoPrecise Antibodies sees 56% increase in 3Q revenue as it continues to advance business

"The ability to select needle-in-the-haystack antibodies using this powerful combination of OmniAb rodent (mouse or rat) immunization and phage display antibody selections provide an entirely new avenue in therapeutic antibody discovery," said Debby Kruijsen, the general manager of the firm's ModiQuest Research subsidiary.

CEO of ImmunoPrecise Jennifer Bath added: "With over 15 years of experience in customized and precision-based phage display, IPA has coupled this powerful technology with Ligand's OmniAb transgenic rodent platforms to enable the accelerated discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy and the lowest immunogenicity."

The company added that data generated during the large pharma and OmniAb collaboration will be publicly presented at conferences in Munich and Boston in March and May respectively as well as via live webinar.

Last week, the antibody discovery firm told investors it had increased revenue and gross margins in the third quarter, as it continues to grow the core business.

Global antibody services

The British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.

The group's acquisitions of Netherlands-based U-Protein and ModiQuest had helped boost revenue in the quarter to end-January to around $2.69 million, it said, compared to the same period in 2018.

Gross margin rose 58% to around $1.57 million from $989,203 in 2018, it added, mainly due to the group focusing on higher margin projects at its new B-cell lab in Victoria, British Columbia and further operational efficiencies put into its operations.

Shares in Toronto added around 4% on Monday at $0.75.

Contact Giles at [email protected]

Follow him on Twitter@Gile74

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 0.58 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $39.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 04/02/2019

2 min read